Quintiles Transnational Corp plans to file for IPO in 18 mths

By Admin
Quintiles Transnational Corp is planning to file for the IPO in next 18 months, the news reports said, citing two people familiar with the situation. Q...

Quintiles Transnational Corp is planning to file for the IPO in next 18 months, the news reports said, citing two people familiar with the situation.

Quintiles is the biggest provider of testing and drug-trial services to pharmaceutical companies. This company was brought in 2008 by private equity companies like TPG Capital and Bain Capital LLC in a deal worth the company at $3.8 billion.

Quintiles is a contract-research company whose revenue growth has accelerated as the drugmakers outsource trials and testing. The company has also appointed a new Chief Executive Officer Tom Pike in April and has brought up a small competitor.

During the past 12 months, Quintiles had $3.53 billion in sales, more than a quarter of the market made up by the 10 biggest contract research companies. It had research partnerships with London-based AstraZeneca Plc, Tokyo-based Eisai Co and Takeda Pharmaceutical Co based in Japan.

TPG and Bain brought Quintiles from One Equity Partners, the private-equity arm of JP Morgan Chase & Co. 3i Group Plc III and Temasek Holdings Pte, Singapore’s state-owned investment company also owns stakes in Quintiles.

Quintiles is a fully integrated biopharmaceutical services company. It offers clinical, commercial, consulting and capital solutions worldwide. The company helps biopharmaceutical companies develop and commercialize products to improve and lengthen patients’ lives. 

Share
Share

Featured Articles

Oracle: Interoperable Healthcare Systems 'Vital'

World's largest database management company Oracle stresses importance of inoperable healthcare systems for improving patient outcomes

Workplace Health Provision Easing Burden on Public Health

A Q&A with David Joerring, Founder & CEO of HealthKey, which connects health insurers and employers with digital health providers through API integrations

Healthcare Business roundup: Baxter, Sanofi & Eli Lilly

Baxter International to sell kidney care spin-off Vantive; Sanofi's consumer health unit ‘to be separated’; Eli Lilly to buy Morphic Holding for $3.2bn

Trane Technologies Helping US Hospitals Meet Climate Pledge

Sustainability

Nestlé Health Science Targets Weight Loss Side-Effects

Medical Devices & Pharma

Eli Lilly Alzheimer's Drug Kisunla Approved in US by FDA

Medical Devices & Pharma